类风湿关节炎患者的静脉血栓栓塞与癌症风险
基于丹麦人群登记数据,比较2497例类风湿关节炎(RA)合并静脉血栓栓塞(VTE)患者与11672例无VTE的RA患者及12730名一般人群的癌症风险。RA合并VTE患者首年癌症累积发生率为3.2%,高于无VTE的RA患者(2.2%)和一般人群(2.0%);首年IRR分别为1.79和2.12,1至36年IRR分别为1.16和1.33。结论认为VTE可能是RA患者隐匿性癌症的标志。
要点
- RA合并VTE患者首年癌症累积发生率为3.2%,无VTE的RA患者为2.2%,一般人群为2.0%。
- RA合并VTE vs 无VTE的RA患者:首年癌症IRR为1.79(95%CI 1.37-2.33)。
- RA合并VTE vs 一般人群:首年癌症IRR为2.12(95%CI 1.63-2.76);1至36年IRR为1.33(95%CI 1.15-1.53)。
核心结论
- RA合并VTE患者在VTE后首年及更长随访期内癌症风险均升高,VTE可能是RA患者隐匿性癌症的标志。
研究设计与样本
- 基于丹麦人群登记数据的队列研究,纳入1978-2013年间首次诊断VTE的RA患者及对照队列。
- 共三组:2497例RA合并VTE患者、11672例无VTE的RA患者、12730名一般人群。
主要发现
- 首年癌症累积发生率:RA合并VTE患者3.2%,无VTE的RA患者2.2%,一般人群2.0%。
- 首年癌症IRR:RA合并VTE vs 无VTE的RA患者为1.79(95%CI 1.37-2.33);RA合并VTE vs 一般人群为2.12(95%CI 1.63-2.76)。
- 索引日期后1至36年癌症IRR:RA合并VTE vs 无VTE的RA患者为1.16(95%CI 1.00-1.34);RA合并VTE vs 一般人群为1.33(95%CI 1.15-1.53)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Essentials Can venous thromboembolism (VTE) in rheumatoid arthritis (RA) patients be marker of cancer? RA patients with VTE and comparison cohorts from population-based registries were compared. Increased risk of cancer in RA patients with VTE during the first year of VTE was observed. Risk of cancer in RA patients was increased also during the longer period following VTE. SUMMARY: Background It is unknown whether venous thromboembolism (VTE) in rheumatoid arthritis (RA) patients can be a marker of occult cancer. Objectives To examine risk of cancer subsequent to VTE among RA patients compared with risk of cancer in an RA cohort without VTE and in a general population without RA and without VTE. Patients/Methods All RA patients with a first-time diagnosis of VTE (index date) during 1978-2013 and comparison cohorts were identified from population-based registries in Denmark. Results We identified three cohorts: 2497 RA patients with VTE, 11 672 RA patients without VTE and 12 730 persons from the general population. The cumulative incidence of cancer within the first year of the index date was 3.2% among RA with VTE, 2.2% among RA without VTE, and 2.0% in the general population cohort. Incidence rate ratios (IRRs) were 1.79 (95% confidence interval [CI], 1.37-2.33) for RA patients with VTE vs. RA patients without VTE and 2.12 (95% CI, 1.63-2.76) for RA patients with VTE vs. the general population. The IRR of cancer at > 1 to 36 years from the index date among RA patients with VTE was 1.16 (95% CI, 1.00-1.34) compared with the RA patients without VTE and 1.33 (95% CI, 1.15-1.53) compared with the general population. Conclusions We found an increased risk of cancer in RA patients with VTE during the first year following VTE and also during the longer follow-up period. Thus, VTE may not only be a result of inflammation and immunological dysfunctions associated with RA, but may also be a marker for occult cancer.
引用
- Pedersen AB, Vandenbroucke J, Horváth-Puhó E, et al. Venous thromboembolism and risk of cancer in patients with rheumatoid arthritis. J Thromb Haemost. 2017. PMID: 28913891. doi:10.1111/jth.13846
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。